Pyoderma gangrenosum is a rare inflammatory disorder that causes painful, rapidly spreading skin ulcers. We compared the cost-effectiveness of the two most commonly used treatments given in tablet form, ciclosporin and prednisolone.
The STOP GAP study was led by Professor Anthony Ormerod (University of Aberdeen) and Professor Hywel Williams (University of Nottingham), and was run in collaboration with the Nottingham Clinical Trials Unit, the UK Dermatology Clinical Trials Network, the Robertson Centre for Biostatistics and the Centre for Healthcare Randomised Trials (CHaRT). The leading health economist was Prof James Mason (University of Warwick).
Please find here the
- Trial Protocol
- Cohort Study of less severe patients
- Trial Paper
- Cost-effectiveness analysis (open access)
- Further scientific paper
For more info on the study, please visit the Centre for Evidence Based Dermatology at the University of Nottingham.